Exelixis Has Good News Today and More is Expected

Today’s Highlights October 19, 2020

Exelixis and Bristol-Myers Squibb sNDA and sBLA Accepted by the FDA
Exelixis (EXEL) and Bristol-Myers Squibb (This content is for paid subscribers.

Please click here to subscribe or here to log in.

Today’s Highlights
Bristol-Myers Squibb (BMY), Exelixis (EXEL)
October 19, 2020

Tweet Pin It

Other Articles

Intellia Therapeutics: Authorized to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for Hereditary Angioedema

October 6, 2021 0

Reata Pharmaceuticals Plans to Submit Omaveloxolone NDA for Friedreich’s Ataxia in Q1 2022

September 30, 2021 0

AstraZeneca Saphnelo Approved in Japan for Adult Patients with SLE

September 28, 2021 0

Encouraging News from Cassava Sciences

September 22, 2021 0

Search ProhostBiotech

Popular Links
Aerie Pharmaceuticals (AERI) Agenus (AGEN) Alnylam (ALNY) Amgen (AMGN) Array BioPharma (ARRY) AstraZeneca Plc (AZN) Bellicum Pharmaceuticals Inc (BLCM) Bristol-Myers Squibb (BMY) Celgene (CELG) Celldex Therapeutics (CLDX) Cellectis (CLLS) Celyad (CYAD) Compugen (CGEN) CRISPR Therapeutics (CRSP) Editas Medicine Inc (EDIT) Enanta Pharmaceuticals (ENTA) Exelixis (EXEL) Gilead Sciences (GILD) Halozyme Therapeutics (HALO) Illumina (ILMN) ImmunoGen (IMGN) Incyte (INCY) Innoviva (INVA) Intellia Therapeutics (NTLA) Ionis Pharmaceuticals Inc (IONS) Karyopharm Therapeutics Inc (KPTI) Merck (MRK) Moderna Inc (MRNA) Nektar Therapeutics (NKTR) Novartis (NVS) Portola Pharmaceuticals Inc (PTLA) PTC Therapeutics (PTCT) Regeneron Pharmaceuticals (REGN) Regenxbio (RGNX) Rhythm Pharmaceuticals Inc (RYTM) Sangamo Therapeutics Inc (SGMO) Sarepta Therapeutics (SRPT) Seagen Inc (SGEN) Spark Therapeutics Theravance Biopharma (TBPH) Vertex Pharmaceuticals (VRTX) Xoma (XOMA)

Recent

ProhostBiotech Archive
ProhostBiotech Archive
Sign Up for Weekly Emails
First Name

Last Name

Email address:

Exclusive Market Insight

& Scientific analysis

Exelixis Has Good News Today and More is Expected